July 28, 2026 12:13 PM GMT GSK plc | Europe M Update Q2'26 Results: Beat; New cost savings announced AlphaSignals Earnings Reaction Key Takeaways Q2'26 results: group sales beat by 2% driven by Vaccines (Arexvy; 70% of the sales beat), operating profit beat 5%, supported by lower COGs, EPS beat by 7%. Excluding Arexvy, group sales would have been 1% ahead. The group sales beat was supported by Vaccines (8% ahead of Street), with stronger Arexvy (£119m beat; Australian tender deliveries and prior period reba ...